奧賽康(002755.SZ)業績快報:2020年度淨利潤降6.87%至7.27億元
格隆匯 2 月 18日丨奧賽康(002755.SZ)發佈2020年度業績快報,實現營業總收入37.81億元,同比下降16.33%;利潤總額8.32億元,同比下降6.27%;歸屬於上市公司股東的淨利潤7.27億元,同比下降6.87%;基本每股收益0.78元。
2020年度,公司聚焦消化道潰瘍、腫瘤、耐藥菌感染、慢性病四大治療領域,加速產品結構優化升級,不斷鞏固核心競爭優勢。因公司在售產品以供住院患者使用的注射劑為主,上半年受疫情影響,產品銷售下降幅度較大,隨着國內疫情得到有效控制,下半年公司業務逐漸恢復至正常水平。同時,公司對研發管線進行結構調整,持續加大創新藥研發投入力度,重點聚焦小分子靶向創新藥物研發,並圍繞腫瘤免疫領域佈局生物創新藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.